{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.32","upperLimit":"0.82","value":"0.58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Response pre-RT/post-CT was defined as follows with overall response defined as achieving PR or CR.\n\nComplete Response (CR): Complete resolution of all initially demonstrable tumor on MRI or CT evaluation w/o appearance of any new areas of disease; negative CSF cytology. Partial Response (PR): \\>/= 50% decrease in the sum of the products of the maximum perpendicular diameters of the tumor (sum LD) relative to baseline w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Stable Disease (SD): \\<50% decrease in the sum LD w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Progressive Disease (PD): \\>/= 25% increase in the sum LD relative to baseline, or the appearance of any new areas of disease or appearance of positive cytology after two consecutive negative samples.","dispersionType":"90% Confidence Interval","groups":[{"description":"Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51) Induction Chemotherapy: CT backbone of the IRS-III regimen \\[vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)\\] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.\n\nRadiation Therapy: Pts w/ M0 dz OR M+ dz aged \\<3y received focal RT (3D conformal or intensity-modulated delivery). Pts \\>3y w/ M+ dz rcvd craniospinal irradiation.\n\nContinuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively.","id":"OG000","title":"Multi-agent Intrathecal and Systemic CT With RT (Modified IRS"}],"paramType":"NUMBER","populationDescription":"The pre-RT CT response evaluable population is defined as patients who completed chemotherapy per protocol.","reportingStatus":"POSTED","timeFrame":"Assessed at study entry and pre-RT/post-CT at week 7.","title":"Pre-Radiation Therapy Chemotherapeutic Response","type":"SECONDARY","unitOfMeasure":"proportion of evaluable patients"}